{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T21:09:36Z","timestamp":1719263376596},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,9,20]]},"DOI":"10.1001\/jama.2022.11526","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T15:03:17Z","timestamp":1663686197000},"page":"1047","source":"Crossref","is-referenced-by-count":4,"title":["Tocilizumab as a Novel Therapy for Steroid-Dependent Polymyalgia Rheumatica"],"prefix":"10.1001","volume":"328","author":[{"given":"Brendan","family":"Antiochos","sequence":"first","affiliation":[{"name":"Johns Hopkins, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"2","key":"jed220053r1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/ard.12.2.98","article-title":"A rheumatoid syndrome occurring in the elderly.","volume":"12","author":"Bagratuni","year":"1953","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"jed220053r3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/ard.16.2.230","article-title":"Myalgic syndrome with constitutional effects; polymyalgia rheumatica.","volume":"16","author":"Barber","year":"1957","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"jed220053r4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semarthrit.2017.04.001","article-title":"Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015.","volume":"47","author":"Crowson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"jed220053r5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis.","volume":"347","author":"Salvarani","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"jed220053r6","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/rheumatology\/kew202","article-title":"Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study.","volume":"55","author":"Sondag","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"jed220053r7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3899\/jrheum.130946","article-title":"Joint involvement in patients with early polymyalgia rheumatica using high-resolution ultrasound and its contribution to the EULAR\/ACR 2012 classification criteria for polymyalgia rheumatica.","volume":"41","author":"Weigand","year":"2014","journal-title":"J Rheumatol"},{"issue":"1","key":"jed220053r8","first-page":"65","article-title":"Relapse in a population based cohort of patients with polymyalgia rheumatica.","volume":"32","author":"Kremers","year":"2005","journal-title":"J Rheumatol"},{"issue":"22","key":"jed220053r9","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review.","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"jed220053r10","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial.","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"jed220053r11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis.","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"jed220053r12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.","volume":"51","author":"Spiera","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"jed220053r13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study.","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"jed220053r14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A disease activity score for polymyalgia rheumatica.","volume":"63","author":"Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"jed220053r15","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/acr.v73.12","article-title":"Mortality among patients with polymyalgia rheumatica: a retrospective cohort study.","volume":"73","author":"Partington","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"jed220053r2","author":"Kersley","year":"1951"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2796398\/jama_antiochos_2022_ed_220053_1663338175.43604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T18:13:48Z","timestamp":1676830428000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2796398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,9,20]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.11526","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}